OverviewChartProfileKey statisticsFinancialsTechnicalNews
Derivatives
TraderScreen

ROCHE I/  CH0012032113  /

SIX Swiss Exchange
2024-11-08  5:31:57 PM Chg. -2.00 Volume Bid9:51:06 PM Ask9:51:06 PM Market Capitalization Dividend Y. P/E Ratio
285.00CHF -0.70% 13,530
Turnover: 3.87 mill.		 -Bid Size: 4 286.80Ask Size: 3 243.32 bill.CHF 3.33% 19.79
TeleTrader 10-23 Roche's Q3 sales up 6% to 15.1B Swiss francs
Newsfile Corp 10-11 JRR Marketing Announces Launch of New Book "5 Ways to Get Strangers to Want to Buy Your Stuff" to He...
Newsfile Corp 10-02 First Phosphate Corp. communique la publication d'une note de recherche universitaire relative aux g...
GlobeNewswire 08-26 First Patient Dosed with LIXTE’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborat...
GlobeNewswire 08-19 LIXTE Biotechnology Provides Update On Recent Activities and Developments
TeleTrader 07-25 Europe lower premarket as earnings pour in
TeleTrader 07-25 Roche's H1 sales at 29.85 billion Swiss francs
GlobeNewswire 06-27 Arch Biopartners Announces GMP Manufacturing of Cilastatin Drug Product
GlobeNewswire 06-18 Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for ...
GlobeNewswire 06-14 LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon...
GlobeNewswire 06-11 Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D ...
TeleTrader 05-27 Roche shuffles its executive committee
TeleTrader 05-16 Roche notes progress in obesity drug trial
GlobeNewswire 05-09 US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson...
GlobeNewswire 05-07 Enable Injections Expands Strategic Partnership with Roche
TeleTrader 04-24 Roche's logs 14.4 billion Swiss francs in Q1 sales
GlobeNewswire 04-03 UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Inju...
GlobeNewswire 04-02 Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting C...
GlobeNewswire 03-14 Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides C...
GlobeNewswire 02-26 Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Ro...
GlobeNewswire 02-21 REPARE ALERT: Bragar Eagel & Squire, P.C. is Investigating Repare Therapeutics Inc. on Behalf of Rep...
TeleTrader 02-01 Roche's 2023 sales increase 1% to 58.7B Swiss francs
GlobeNewswire 01-29 Carmot Therapeutics Announces Completion of Acquisition by Roche
GlobeNewswire 01-03 US Neurologists Optimistic Regarding the Huntington’s Disease Treatment Pipeline, Emphasizing Haltin...
GlobeNewswire 01-03 Arch Biopartners Receives Approval from the Turkish Ministry of Health to Proceed with Phase II Tria...